• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Singapore
    • Novartis Site Directory
Novartis logo: a global healthcare company
  • Our Work
    • Clinical Trials
    • Therapeutic Areas
    • Healthcare Professionals
  • About Us
    • Our Mission and Vision
    • Our Culture and Values
    • Our Strategy
    • Our Leadership
    • Company History
    • Corporate Responsibility
    • Contact Us
  • Products
    • Product Portfolio
    • Product Listing
  • News
    • Featured News
    • Media Releases
    • In The News
    • Stories
    • Global News
  • Careers
    • Careers Search
    • Working at Novartis
    • Awards & Recognition
    • Learning and Development
Search
Chronic Myeloid Leukemia
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
  • Jump to Comments
Stories/Education & Awareness

Kaliammal’s story: Her Journey from Progression to Remission in Chronic Myeloid Leukemia (CML)

Sep 26, 2019

Every year, approximately 20 to 30 new cases of Chronic Myeloid Leukemia (CML) is being diagnosed in Singapore (Source: Cancer Registry Report 2015). Madam Kaliammal is one of them. This is her story.

 

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Contains Video
Advanced breast cancer patients in Singapore
Education & Awareness

Understanding advanced breast cancer patients in Singapore

Contains Video
Transforming Transplantation: Story of Lucy and Hock Seng
Education & Awareness

Transforming Transplantation: Story of Lucy & Hock Seng

Contains Video
migrane-get-ahead-of-pain
Education & Awareness

Get ahead of pain

You are here

  1. Home ›
  2. Stories ›
  3. Hope

Novartis Singapore

  • Our Work
  • About Us
  • Products
  • News
  • Careers
  • Contact Us
  • Locations

Subscribe to Novartis

  • Facebook
  • Twitter
  • YouTube
  • LinkedIn
  • Instagram
  • Novartis Site Directory
© 2022 Novartis AG

This site is intended for an audience in Singapore.

  • Terms of Use
  • Privacy Policy
  • Healthcare Professionals